➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Express Scripts
McKesson
Medtronic
Harvard Business School

Last Updated: August 14, 2020

DrugPatentWatch Database Preview

Litigation Details for Eagle Pharmaceuticals, Inc. v. Slayback Pharma LLC (D. Del. 2018)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in Eagle Pharmaceuticals, Inc. v. Slayback Pharma LLC
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Eagle Pharmaceuticals, Inc. v. Slayback Pharma LLC (D. Del. 2018)

Date Filed Document No. Description Snippet Link To Document
2018-12-11 1 Complaint (“the ’797 patent”); and 10,010,533 (“the ’533 patent”) (collectively, “the Patents-in-Suit”). …COUNT IV – INFRINGEMENT OF U.S. PATENT NO. 10,010,533 UNDER 35 U.S.C. § 271(e)(2) … INFRINGEMENT OF U.S. PATENT NO. 10,010,533 94. Eagle incorporates…infringement of the ’831 patent, the ’796 patent, the ’797 patent, and the ’533 patent. (b…of Eagle’s U.S. Patent Nos. 9,265,831 (“the ’831 patent”); 9,572,796 (“the ’796 patent”); 9,572,797 (“ External link to document
2019-01-11 17 Redacted Document (“the ‘797 patent”); and 10,010,533 (“the ‘533 patent”) (collectively, the “patents-in-suit”), which …infringes U.S. Patent Nos. 9,265,831 (“the ‘831 patent”); 9,572,796 (“the ‘796 patent”); 9,572,797 (“… the patents-in-suit. Rather, Plaintiff’s complaint alleges that Slayback infringes the patents-in-suit…infringe any claim of the patents-in-suit. All of the independent claims of these patents require a pharmaceutically…equivalents to prove infringement of the patents-in-suit. “[W]hen a patent drafter discloses but declines to External link to document
2019-02-12 23 Redacted Document “’831 Patent”); 9,572,796 (the “’796 Patent”); 9,572,797 (the “’797 Patent”); and 10,010,533 (the “’… four patents listed in the Orange Book and covering the formulation of Belrapzo®. U.S. Patents 9,265,831…“’533 Patent”) (the “Patents-in-Suit”) list inventors Nagesh Palepu and Philip Buxton. Certain claims…Plaintiff Plausibly Pled that Slayback Infringes the Patents-in-Suit............8 3. … questions over the proper interpretation of a patent’s intrinsic record are “not suitable” and “particularly External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Boehringer Ingelheim
AstraZeneca
Moodys
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.